Best Hematology Companies in United States
The 163 best Hematology companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Orca Bio.
Ranking the most-funded Hematology companies across the United States, this directory tracks 163 ventures carrying $3.5 billion in total disclosed funding, one unicorn, and a market expanding at a 6.5% CAGR on the back of aging demographics and surging demand for modern analyzers. That's real capital, not projections. Orca Bio leads at $300 million raised, followed by Inquis Medical at $115 million and STAR Therapeutics at $90 million. The rest of the field is smaller but moving fast, with HHS, OrbiMed, and Alexandria among the most active backers writing checks across the stack.
So what's driving the heat right now? Coverage in the sector is flat, but the thematic concentration is sharp: CAR-T approaches to myeloma, stem cell transplant protocols, T-cell lymphoma, and cytogenetic abnormalities in leukemia are pulling the majority of investor attention. Reducing toxicity in cell and gene therapy is an open problem that I'd argue is the single biggest regulatory friction point for this cohort right now, and a recent study on blood disorder burden in Long Island underscores how uneven the disease load remains across geographies. If you're mapping this space, the funding tells you where conviction lives.
Ranked: Best Hematology companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Orca Bio 🦄 Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders 74Funding top 18%Growth top 26%Moat top 26%Talent top 38% All 8 signals ▾Fundingtop 18% Growthtop 26% Moattop 26% Talenttop 38% Techtop 40% Markettop 42% Globalbottom 37% Newsbottom 18% Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $300M | 5 mo ago | 66 | Jeroen Bekaert Co-Founder & COO | WordPressApple iCloud MailGoogle Workspace+29 | — | 1 expansion |
| 2 | Anthos Therapeutics Developer of novel anticoagulants for thrombosis treatment | $250M | 87 mo ago | 10 | Paris Panayiotopoulos Co-Founder | WordPressApple iCloud MailMicrosoft 365+23 | — | — |
| 3 | Ensoma Developer of in vivo hematopoietic stem cell engineering for genomic medicine | $205M | 37 mo ago | 52 52 → 51 (-2%) | — | — | 62 patents Adenoviral gene‑therapy vectors enabling multi‑lineage therapeutic expression and stem‑cell mobilization | — |
| 4 | Disc Medicine Developer of therapeutics for the treatment of hematologic diseases | $202M | 40 mo ago | 23 | Brian Donald Founder & CEO | TurbopackApple iCloud MailMicrosoft 365+17 | 133 patents Therapeutics modulating iron regulation for anemia and myeloproliferative diseases | — |
| 5 | Magenta Therapeutics Developer of stem cell-based therapies for autoimmune disease, genetics blood disorders and cancer | $150M | 61 mo ago | 75 | — | — | 347 patents Hematopoietic stem cell mobilization and targeted antibody‑drug conjugates for transplantation | — |
| 6 | La Jolla Pharmaceutical Innovating critical care and infectious disease therapies for global health | $148M | 97 mo ago | 71 | — | — | — | — |
| 7 | Accriva Diagnostics Develop products/systems for diagnostics. | $144M | 135 mo ago | 399 | — | — | — | — |
| 8 | Acetylon Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $138M | 154 mo ago | 37 | Marc Cohen Co-Founder | — | — | — |
| 9 | Ajax Developer of targeted therapies for the treatment of hematologic malignancies | $135M | 25 mo ago | — | Olli Silvennoinen Co-Founder | WordPressMySQLPHP+14 | — | — |
| 10 | Tasso Developer of blood collection device for diagnostic applications | $131M | 54 mo ago | 104 | Erwin Berthier CTO and Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+25 | 106 patents Microfluidic devices for automated collection and handling of bodily fluids | 1 award |
| 11 | Inquis Medical Developer of medical device for the treatment of peripheral thrombectomy | $115M | 5 mo ago | — | Mojgan Saadat Co-Founder | — | — | 1 launch |
| 12 | YourBio Health Manufacturer of push-button blood collection device | $102M | 57 mo ago | 32 32 → 19 (-41%) | Yuran Li Managing Director | WordPressMySQLPHP+16 | — | — |
| 13 | Accumetrics Platelet function analysis | $98M | 158 mo ago | 46 | — | — | 60 patents Platelet function diagnostics and aggregation monitoring for antiplatelet therapy assessment | — |
| 14 | Keros Therapeutics Developer of small molecules to treat hematologic and musculoskeletal disorders | $90M | 75 mo ago | 136 136 → 118 (-13%) | — | DrupalPHPAmazon Web Services+22 | 173 patents Engineered activin receptor and GDNF fusion protein therapeutics for regenerative medicine | — |
| 15 | STAR Therapeutics Developer of antibody therapies for multiple diseases 40Funding top 21%Moat top 42%Talent bottom 49%News bottom 45% All 6 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Newsbottom 45% Marketbottom 42% Globalbottom 38% Funding: Raised $90.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $90M | 8 mo ago | 43 | Adam Rosenthal Founder & CEO | — | — | — |
| 16 | Spotlight Therapeutics Developer of cancer therapeutics using gene editing | $81M | 32 mo ago | 32 | — | — | — | — |
| 17 | Akura Medical Developer of catheter-based thrombus removal device | $60M | 32 mo ago | 30 | — | — | — | — |
| 18 | CERo Therapeutics Developer of platforms for cellular immunotherapy | $56M | 13 mo ago | 15 15 → 16 (+7%) | — | Node.jsUbuntuBootstrap+15 | — | — |
| 19 | ExThera Medical Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking | $55M | 57 mo ago | 23 | — | WordPressMySQLPHP+23 | 151 patents Extracorporeal blood filtration and glycocalyx-modulating therapies for disease treatment | — |
| 20 | Inari Medical Pioneering innovative medical devices for venous thromboembolism treatment | $52M | 98 mo ago | 696 696 → 666 (-4%) | — | DrupalApple iCloud MailMicrosoft 365+24 | 347 patents Endovascular clot removal and aspiration catheter systems for neurovascular thrombectomy. | — |
| 21 | Velano Vascular Provider of a needle-free blood collection device | $51M | 78 mo ago | 19 | Tom Polen CEO | — | 202 patents Advanced vascular access connectors and fluid transfer catheter systems for IV therapy | — |
| 22 | Sideris Pharmaceuticals Therapeutics for the treatment of transfusion-related iron overload. | $50M | 151 mo ago | 5 | — | — | — | — |
| 23 | Jasper Therapeutics Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | $49M | 77 mo ago | — | Judith Shizuru Co-Founder | WordPressApple iCloud MailMicrosoft 365+21 | — | — |
| 24 | CytoPherx Cytopheresis systems for inflammatory conditions | $48M | 173 mo ago | — | Charles Fisher CEO | — | 46 patents Extracorporeal cytopheresis cartridges for targeted cell removal and cardiac function enhancement | — |
| 25 | Veralox Therapeutics Developer of small molecules for treating thrombosis and diabetes pathologies | $47M | 35 mo ago | 6 | Matthew Boxer Co-Founder and COO | — | — | — |
| 26 | Babson Diagnostics Provider of blood testing service using microsamples collected from a finger. | $45M | 59 mo ago | 57 57 → 54 (-5%) | Eric Olson Founder | Craft CMSPHPUbuntu+12 | 22 patents Automated blood sample handling and centrifugation for point‑of‑care diagnostics | 1 launch · 1 partnership |
| 27 | Epifrontier Developer of epigenetic therapeutics targeting hemoglobinopathies like sickle cell disease | $32M | 2 mo ago | — | Ko Kikuzato Co-Founder | — | — | — |
| 28 | Entegrion Provider of hemostasis and fluid replacement products | $30M | 47 mo ago | 4 | John Mowell CEO - Chairman | — | 112 patents Hemostatic textiles and point‑of‑care coagulation monitoring devices for surgical bleeding control | — |
| 29 | Cellphire Therapeutics Developer of platelet-derived therapeutics to address bleeding control and hemostasis challenges | $25M | 6 mo ago | 51 51 → 48 (-6%) | Mike Gaffney CEO | — | — | — |
| 30 | Glycan Therapeutics Developer of glycan-based therapeutics for coagulation and thrombo inflammation | $23M | 14 mo ago | 4 | Yongmei Xu Co-Founder
| TypeScriptBootstrapZone.js+9 | — | — |
| 31 | Jana Care Provider of mobile-based healthcare diagnostics for diabetes prevention 53Innovation top 27%Funding top 30%Product top 32%Moat top 39% All 8 signals ▾Innovationtop 27% Fundingtop 30% Producttop 32% Moattop 39% Markettop 45% Talentbottom 49% Globalbottom 39% Techbottom 22% Innovation: 3 product lines · Deep-tech classification: Tech Hardware Funding: Raised $17.7M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $18M | 3 mo ago | 60 | Anh Hoang Chief Executive Officer | — | — | — |
| 32 | Illexcor Therapeutics Developer of therapeutics for hematologic diseases | $17M | 2 mo ago | — | Andrew Fleischman Co-Founder & CEO | — | — | — |
| 33 | Immutrix Therapeutics Innovating blood filtration technologies for critical care and unmet medical needs | $14M | 9 mo ago | 22 | Carol Rae Founder & CEO | — | — | — |
| 34 | IMMvention Developer of anti-inflammatory therapies for neurodegenerative and cardiometabolic diseases | $9M | 41 mo ago | 10 | Jenny Ting Co-Founder | — | — | — |
| 35 | FYR Diagnostics Provider of in-vitro diagnostic tests for the detection of diseases | $8M | 22 mo ago | 14 | — | — | — | 1 launch |
| 36 | Hemex Health Portable diagnostic devices empowering healthcare frontlines with affordable, accurate testing | $6M | 21 mo ago | 26 | — | Cart FunctionalitySquarespace CommerceSquarespace+23 | 89 patents Point‑of‑care diagnostic devices using electrophoresis, sonication and enhanced imaging for health assays | 1 partnership |
| 37 | Haima Therapeutics Developer of therapeutics for the treatment of bleeding and other ailments | $6M | 14 mo ago | 6 | Christa Pawlowski Co-Founder | — | — | — |
| 38 | RegenLab Provider of medical devices to develop cellular therapies | $5M | 11 mo ago | 76 | Giuseppe Calloni CEO | WordPressMySQLPHP+19 | — | — |
| 39 | Retham Technologies Developer of diagnosis and management of blood clotting disorder | $5M | 14 mo ago | 3 | — | — | — | — |
| 40 | Vivacelle Bio Developer of nano-micelles technology-based colloids for restoring blood pressure | $4M | 16 mo ago | 4 | Harven Deshield Jd Chief Executive Officer | — | — | — |
| 41 | FloBio Point-of-care diagnostic platform | $4M | 16 mo ago | 6 | Scott Diamond Founder | — | 6 patents Medical diagnostic platforms for coagulation, platelet function, and drug effect analysis | — |
| 42 | IHP Therapeutics Developer of a self-administered treatment for sickle cell disease vaso-occlusive crisis | $4M | 9 mo ago | — | Robert Van Gorp Co-Founder | — | — | — |
| 43 | SelSym Developer of therapeutics for hemostasis and wound healing | $3M | 9 mo ago | 5 | — | — | — | — |
| 44 | Sanguina Innovative blood health monitoring and wellness solutions for proactive health management | $3M | 34 mo ago | 18 | — | ShopifyVenmoPayPal+10 | 6 patents AI-driven imaging analysis for quantitative anemia diagnosis and capillary refill assessment | — |
| 45 | GeneVentiv Therapeutics Developer of therapeutic solutions for the treatment of hematology disorders | $1M | 13 mo ago | 2 | Damon Race CEO & President | — | — | — |
| 46 | KaloCyte Developer of a nanotechnology-based red blood cell substitute | $1M | 12 mo ago | 8 | Dipanjan Pan Co-Founder | WordPressApple iCloud MailZoho+23 | 28 patents Lipid nanoparticle oxygen carriers for hemorrhagic shock and bio‑synthetic nanoparticle clearance | — |
| 47 | DesiCorp Developer of freeze-dried blood product for blood transfusion | $1M | 3 mo ago | 4 | Jonathan Kopechek Co-Founder | — | 3 patents Adjustable loading devices for handling agricultural products | — |
| 48 | HemoGenyx Developer of cell and gene therapies to treat blood diseases and viral infections | $1M | 4 mo ago | 14 | — | WordPress Block EditorWordPressMySQL+8 | 6 patents Bispecific antibody-mediated depletion of hematopoietic stem/progenitor cells for conditioning transplants | — |
| 49 | Levisonics Developer of hemostatic assays | $974K | 24 mo ago | 4 | Damir Khismatullin Co-Founder & President | — | 2 patents Acoustic levitation containment cartridges and apparatuses for manipulating particles | — |
| 50 | Von Vascular Developer of medical devices for thrombectomy procedures | $693K | 14 mo ago | — | Manning Hanser CEO | — | — | — |
Top 12 Hematology companies in United States
#1
Orca Bio 🦄Series F · Menlo Park, California · founded 2016 · 66 employees$300Mraised▾
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patient's new immune system.
- Jan 2026Series F$250M
- Nov 2019Series D$192M
#2
Series C · Redwood City, California · founded 2019$115Mraised▾
Developer of medical device for the treatment of peripheral thrombectomy. It offers AVENTUS Precision Thrombectomy System that is designed to treat venous thromboembolic diseases such as pulmonary embolism and deep vein thrombosis.
- Jan 2026Series C$75M
- Nov 2024Series B$40M
#3
Funding Raised · Pennington, New Jersey · founded 2025$32Mraised▾
Developer of epigenetic therapeutics targeting hemoglobinopathies like sickle cell disease. The company is creating oral therapies designed to increase fetal hemoglobin. Its lead program focuses on sickle cell disease, with potential expansion to other conditions. The goal is to provide accessible treatments worldwide, especially in resource-limited regions.
- Mar 2026Grant (prize money)$32M
#4
Series A · Richmond, Virginia · founded 2020$17.3Mraised▾
Developer of therapeutics for hematologic diseases. The company is focused on developing oral Hemoglobin S polymerization inhibitors that can provide profound disease-modifying clinical benefits of sickle cell disease.
- Apr 2026Series A$13M
- Mar 2025Seed—
- Jan 2021Grant (prize money)$1.9M
- Aug 2020Grant (prize money)$2.2M
#5
Series C · Newton, New Jersey · founded 2011 · 60 employees$17.7Mraised▾
JanaCare is a healthcare technology startup providing a diagnostic device and a mobile-based platform for diabetes management. The device can measure blood glucose, lipids, creatinine, and hemoglobin. Its Habits program available both on the web and through a mobile application is based on the diabetes prevention program curriculum. The mobile app "food: habits" tracks user's calories and fat intake provides suggestions for meals, aids to set calorie burning and weight loss goals.
- Mar 2026Series C$1.4M
- Mar 2025Series C$2.9M
- Oct 2023Series C$13.1M
- Nov 2022Series B$575.3K
#6
Series D · San Francisco, California · founded 2018 · 43 employees$90Mraised▾
Developer of antibody therapies for multiple diseases. The company is developing antibody drug discovery to generate drug programs that target multiple diseases with a single therapy. Its lead candidate ELA026 is a monoclonal antibody specifically designed to address severe inflammatory disorders. The company is addressing drugs for immunology, immuno-oncology, and rare hematologic diseases.
- Sep 2025Series D$125M
- Sep 2023Series C$90M
#7
Series A · Rockville, Maryland · founded 2005 · 51 employees$25.3Mraised▾
Developer of platelet-derived therapeutics to address bleeding control and hemostasis challenges. The company develops stabilized cellular products like freeze-dried hemostatic agents and cryopreserved platelets targeting trauma, surgery, and military applications.
- Nov 2025Conventional Debt$3M
- Aug 2022Series A$5M
- Apr 2021Series A$15M
- Jun 2017Series A$3M
#8
Public · San Francisco, California · founded 2016 · 15 employees$56.1Mraised▾
CERO Therapeutics is developing platforms for cellular immunotherapy. It has developed a hybrid platform that integrates innate and adaptive programs to eliminate the disease. The company has not disclosed the details of its platform as of May 2019.
- Apr 2025Post IPO$5M
- Sep 2024Post IPO$1.2M
- Feb 2024Series A$10.2M
- Nov 2019Series A$43.2M
#9
Series A · Rapid City, South Dakota · founded 2009 · 22 employees$14Mraised▾
Innovating blood filtration technologies for critical care and unmet medical needs. The company develops cutting-edge extracorporeal blood-filtration technologies, addressing urgent, unmet medical needs. Their lead innovation is a proprietary hemoperfusion device, a dialysis-like procedure that removes harmful molecules from circulating blood while preserving essential components. This technology targets toxins, poisons, and immune mediators, interrupting pathological cascades that lead to complications. The company's engineered carbon materials rapidly reduce harmful substances from blood, preserving platelets, albumin, and electrolytes. This positions them as a leader in next-generation, rapid-response therapies for acute, acute-on-chronic, and chronic medical conditions. They operate at the intersection of immunology, toxicology, and critical care medicine, focusing on emergency and intensive care. Their research and development efforts are geared towards commercializing proprietary therapeutic treatments using advanced adsorbent technologies, specifically for the removal of drugs and poisons.
- Sep 2025Conventional Debt$480K
- Jul 2020Series A$300K
- Sep 2019Series A$450K
- Oct 2018Series A$5.3M
#10
Funding Raised · Raleigh, North Carolina · founded 2013 · 4 employees$23.3Mraised▾
Developer of glycan-based therapeutics for coagulation and thrombo inflammation.The company is developing drug therapies based on a novel synthetic carbohydrate technology platform. The platform technology can be used to synthesize an anticoagulant drug, like synthetic heparin, as well as design heparin-like oligosaccharides for research and development for other medical applications.
- Apr 2025Grant (prize money)$454.7K
- Apr 2025Grant (prize money)$2.4M
- Sep 2023Grant (prize money)$1.3M
- Sep 2023Grant (prize money)$347.5K
#11
Series A · Louisville, Kentucky · founded 2017 · 4 employees$1Mraised▾
Developer of freeze-dried blood product for blood transfusion. The company is developing freeze-dried red blood cells that can be stored and infused to patients experiencing traumatic blood loss, especially in remote or battlefield settings.
- Mar 2026Series A$840K
- Jul 2024Series A$5.2M
- Feb 2023Grant (prize money)$281.9K
#12
Public · Buffalo, New York · founded 2014 · 14 employees$1Mraised▾
Developer of cell and gene therapies to treat blood diseases and viral infections. It offers apipeline of drug candidates which include HG‑CT‑1 CAR‑T therapy for relapsed or refractory acute myeloid leukemia, CDX Bi‑specific antibody to eliminate malignancy in patients with FLT3+ R/R AML and potentially condition bone marrow transplant, and Chimeric Bait Receptor Platform for antiviral and cancer immune cell reprogramming.
- Feb 2026Post IPO$3.4M
- Mar 2025Post IPO$915.1K
- Jan 2025Post IPO$425.6K
- Mar 2024Post IPO$4.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Hematology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.